Aclaris Therapeutics Received $26.5 M Upfront Plus Is Eligible for Up to $5M in Milestones >ACRS

Aclaris Therapeutics Received $26.5 M Upfront Plus Is Eligible for Up to $5M in Milestones >

Dow Jones19minutes ago

Aclaris Sells Portion of Future Royalty Payments and Milestones From Eli Lilly on Sales of OLUMIANT for Alopecia Areata to OMERS

Aclaris Sells Portion of Future Royalty Payments and Milestones From Eli Lilly on Sales of OLUMIANT for Alopecia Areata to

Dow Jones20minutes ago

Eli Lilly and Co Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 -7.76% Cantor Fitzgerald $885 → $885 Reiterates Overweight → Overweight 07/11/2024 4.22%

BenzingaJul 15 09:05 ET

Incyte, Moderna Among Most Shorted S&P 500 Healthcare Stocks in June

Seeking Alpha13:01 ET

Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793

Eli Lilly (LLY) has an average outperform rating and a price target range of $540 to $1,100, according to analysts polled by Capital IQ.Price: 955.75, Change: +5.29, Percent Change: +0.56

MT NewswiresJul 16 08:18 ET

Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025

Barclays analyst Carter Gould maintains $Eli Lilly and Co(LLY.US)$ with a buy rating, and maintains the target price at $1,025.According to TipRanks data, the analyst has a success rate of 59.5% and

Moomoo NewsJul 16 05:33 ET · Ratings